



Key Statistics

(as of March 2010)

Symbol	BONUE
Exchange	OTC BB
Market Cap	\$24.76M
Shares outstanding	64.22M
Recent Price	\$0.39

Management

Stephen J. Browand
President and CEO

James T. Crane
CPA, Chief Financial Officer

Dr. Andy Kielbania
Chief Scientist

Investor Relations

The Investor Relations Group
11 Stone Street
New York, NY 10004
Tel.: (212) 825-3210
Fax: (212) 825-3229

Investor Relations
Erika Moran
Tom Caden

Public Relations
Laura Colontrelle

Company Overview

BioNeutral Group, Inc. ("BioNeutral") is an exciting specialty life science company that has developed two proprietary chemistry-based product platforms that are environmentally friendly and address a broad array of disinfecting and cleaning applications. The Ygiene™ product platform consists of a family of sporicidal formulations (sterilants) which can be applied to surfaces, skin and fabric. They have been proven to create a sterile environment and eliminate all harmful microorganisms virtually, on contact. A consumer grade formulation has just been tested against the Swine Flu (H1N1) and it is both mild to the skin and works virtually on contact. This technology is extremely important for hospitals and the entire health care sector and for certain industries including food preparation and pharmaceutical manufacturing.

The Ogiene™ product platform neutralizes toxic and noxious gases that cause acid rain and global warming which harm the planet and threaten its inhabitants. Both platforms are utilized in military, industrial, commercial, and consumer applications. BioNeutral expects these products to launch in the first half of 2010 with the company currently in discussions with several potential licensees and distributors.

Investment Highlights

- BioNeutral has developed unique technologies with antimicrobial, odor control, and bionutralizing applications that are focused on the elimination of harmful environmental contaminants, toxins, and health threatening microorganisms.
- The company's lead product platform, Ygiene™, consists of a proprietary family of antimicrobial sporicidal formulations (sterilants) that are unique in the field. They can be applied to surfaces, skin and fabrics and create a virtual on contact sterile environment. Ygiene™ has demonstrated its ability to eliminate all difficult-to-kill microorganisms, including spores and viruses.
- Ygiene™ is environmentally friendly, and leaves no toxic residues. It is water-based and is non-corrosive. Competitive products in the market, such as bleach, quats or silver are typically corrosive and ineffective against the most difficult to kill organisms.
- Ygiene is disruptive proprietary technology that is scalable and addresses significant current problems with a better solution within a worldwide market in excess of \$10 billion a year. It is the fastest acting, ecologically sound, non staining, non corrosive, family of antimicrobial sterilants known.
- BioNeutral's Ogiene™ product platform eliminates toxic and noxious gases and liquids, and can be used to neutralize greenhouse gases and industrial pollutants.
- Independent verification of efficacy, speed, and power of BONU's Ygiene™ antimicrobial using required EPA protocol on the most difficult-to-eliminate microorganisms.
- Multi-billion dollar addressable market. Reckitt Benckiser, the maker of Lysol® products, reported approximately \$9.6 billion in 2008 revenues. BONU's Ygiene™ product has outperformed Lysol® in every independently verified test as well as GoJo's (Purell), Pure Bio (Germ Control 24).
- The company is in the process of certifying its product formulations with the EPA and expects EPA approval for Ygiene™ in H1 10.

BioNeutral Products

- Two Separate Technology Platforms
 - Ygiene™: Antimicrobials
 - Ogiene™: Toxic Gas Neutralizers, Odor Elimination, and Superior Cleaners
- Both Platforms Very Robust
- Easily Customized for Specific Applications
- Water-Based
- Synergistically Utilize Existing Active Ingredients
- Easy Use, Application



Ygiene™

- Fast acting, effective at low and high temperatures, and does not stain.
- Kills spores, including the difficult to kill anthrax spore, and has demonstrated its ability to kill viruses, including H1N1 (swine flu).
- Can be formulated into cleaning products and soaps for hospitals, the hospitality industry, surgical and dental sterilization, and consumer products.
- Environmentally “green” and breaks down into materials that are not harmful.

Characteristics

- BioNeutralizers – Antimicrobials
- Water- and surfactant-based; pH buffered
- Noncorrosive to ferrous metals
- Easily customized for specific applications
- Utilizes existing antimicrobial agents
- Proprietary process – component synergies
- Exceptional speed and broad spectrum efficacy
- Miscible with solvents and water
- Stable

Ygiene family of Products

- Sanitizers
- Disinfectants
- Cold sterilants
- Consumer grades
- Hospital grades
- Industrial grades
- Military/homeland security grades



Independent Testing At ATS Labs


- Independent verification of efficacy, speed, and power of our Ygiene™ antimicrobial using required EPA protocol on the most difficult to eliminate microorganisms
- 99.9999+% eradication of C. diff spores
- 100% eradication of Aspergillus niger, a black mold
- 100% elimination of spores in hospital setting
- Cold sterilant
- Continued testing at ATS using required EPA test methods against antibiotic resistant bacteria - MRSA, swine flu

Ogiene™

- ChemoNeutralizer – Toxic Gases and Odors, Cleaners
- Water-based
- Surfactant-based
- pH buffered
- Easily customized for specific applications
- Proprietary formulation delivery system increases solubility for intimate micelle contact
- Accelerates conversion of toxic and noxious gases

Major Applications

- Multi-purpose cleaners
- Toxic gases
 - » Eliminating smoke and toxins from active fires
 - » Elimination of residuals from fires
 - » Fumes from normal combustion – greenhouse gases
 - » Toxic Gases in Dwellings
 - Formaldehyde
- Noxious Odors
 - » Toilets
 - » Cigarette smoke
 - » Kitchen odors
 - » Sports equipment
 - » Waste treatment facilities
 - » Ventilation systems



Ygiene™ and Ogiene™ Family of Products

- Very robust and broad spectrum
- Can be customized for specific application
- Products available for testing
- Seeking partnering organizations

Disclaimer

The information disseminated by the Investor Relations Group (“IRG,” “us,” “we,” “I” or “it”) is for informational purposes only and does not constitute an offer to sell securities. We do not undertake to provide any investment advice or recommendation for the buying and selling of securities. Companies that are profiled may have engaged our services to perform investor relations services including promotional services and the placement of the profiled companies on our website. IRG compensation for such services has been or will be made in cash and the issuance of securities of the profiled company, the amount or type of compensation is available upon request. We may liquidate any securities that we receive as compensation when deemed appropriate to do so. The assembled information herein is based on information supplied by the company, press releases, SEC filings and other sources believed to be reliable as of the date of the report on the featured companies, but no representation or implied or made as to its accuracy, completeness or correctness. It is subject to change without notice. IRG and its affiliates are not, nor claim to be: brokers, broker-dealers, market makers, investment bankers, advisors, analysts or underwriters. Information in email alerts, Fact Sheets and other forms of informational media provided by us will contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Forward-looking statements are subject to a number of known and unknown risks and uncertainties outside our control that could cause actual operations or results to differ materially from those anticipated. The cautionary statements made herein should be read as being applicable to all related forward-looking statements wherever they appear in this or in other communications. We encourage you to visit the Securities Exchange Commission Website at <http://www.sec.gov>.